Dr. Dan Liu joined Pivotal bioVenture Partners China in 2024 and is currently the Managing Partner of Pivotal China, where he leads the investment team and oversees business operations. He has previously served as a Senior Partner, Managing Partner and Investment Committee Member in several funds at CDH Investments, in charge of healthcare investments. Dr. Liu has led tens of successful investments, such as GemPharmatech (688046.SH), HitGen (688222.SH), I-Mab (IMAB.O), Maixin (acquired by BSBE), and serves on the boards of several public and private companies. Prior to CDH, Dr. Liu worked at Bain & Company, serving in management consulting leadership team, where he was the key professional of Asia Healthcare practice. Together Dr. Liu has 20 years of experience in many fields of Life Sciences, including research, business, consulting and investment. Dr. Liu also serves as a member in several industry association panels and boards.
